Recent Biotechnology Acquisitions in Tennessee

Acquisition Volume in Biotechnology in Tennessee by Year

Last 5 years

Acquisition volume by year Annual acquisition counts for the last 5 years for Recent Biotechnology Acquisitions in Tennessee. 1 2022 0 2023 0 2024 0 2025 ~0 est. 0 2026
Actual Full-year estimate
  • Buyer
    Tesis Biosciences
    Target
    Genome Explorations Inc.
    Industry
    Biotechnology
    Type
    Buyout

    Tesis Biosciences has acquired Genome Explorations to accelerate its clinical research and product development efforts in targeted genetic sequencing and precision medicine. The acquisition brings Genome Explorations’ genomic profiling and molecular diagnostics capabilities and clinical research staff into Tesis’ integrated platform to speed development of proprietary therapeutics and diagnostic products.

  • Buyer
    Charles River Laboratories International, Inc.
    Target
    Cognate BioServices, Inc.
    Seller
    EW Healthcare Partners, Medivate Partners, BlackRock, Unnamed sovereign wealth fund
    Industry
    Biotechnology
    Type
    Buyout

    Charles River Laboratories agreed to acquire Cognate BioServices for approximately $875 million in cash, expanding Charles River's capabilities into the high-growth cell and gene therapy CDMO sector. Cognate, headquartered in Memphis, Tennessee with over 500 employees, will provide Charles River integrated cell and gene therapy development, testing, and CGMP manufacturing capabilities; the deal was expected to close by end of Q1 2021.

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.

Related Acquisition Pages